Forecasting Stories
Our latest forecast of Chicken (USA Stocks:CSSE)
 | 4 hours ago at Macroaxis By Nico Santiago |
Chicken Soup for the Soul Entertainment (CSSE) has recently experienced a notable price increase of 3.7%, stirring interest among investors who are tracking its performance in the Entertainment industry. Despite the company's projected loss with an EPS estimate for next year at $3.57, the stock has managed to climb above its 200-day moving average of $1.34, which could be interpreted as a bullish signal. However, with a relatively high mean deviation of 3.03 and a substantial short interest of 1.9M shares from the previous month, indicating that a significant number of investors are betting against the stock, caution is advised. Continue Reading...
- CSSE Chicken Soup For
- Latest Give this chicken noodle soup from Nepal called thukpa a try on a ... - Houston Chronicle
- CSSE 0.27 -0.01
- Low 0.27
- High 0.29
- Volume 209.6 K
- Alpha -0.56
- Beta -0.54
- Return On Equity -4.68
- Return On Asset -0.14
- Profit Margin (0.45) %
- Operating Margin (0.32) %
- Current Valuation 539.56 M
- Shares Outstanding 23.73 M
- Shares Owned By Insiders 28.96 %
- Shares Owned By Institutions 33.50 %
- Number Of Shares Shorted 1.88 M
- Price To Earning 5.06 X
- Price To Book 0.45 X
- Price To Sales 0.0223 X
- Revenue 252.81 M
- Gross Profit 31.26 M
- EBITDA (69.69 M)
- Net Income (101.95 M)
- Cash And Equivalents 23 M
- Cash Per Share 1.53 X
- Total Debt 497.73 M
- Debt To Equity 1.54 %
- Current Ratio 1.54 X
- Book Value Per Share 0.60 X
- Cash Flow From Operations (62.94 M)
- Short Ratio 11.33 X
- Earnings Per Share (8.22) X
- Target Price 2.56
- Number Of Employees 1.33 K
- Beta 1.27
- Market Capitalization 8.93 M
- Total Asset 883.88 M
- Retained Earnings (247.75 M)
- Working Capital (25.35 M)
- Z Score -0.39
- Net Asset 883.88 M
- Accumulation Distribution 14455.24
- Daily Balance Of Power (0.50)
- Rate Of Daily Change 0.96
- Day Median Price 0.28
- Day Typical Price 0.28
- Price Action Indicator (0.015)
Macroaxis uses a strict editorial review process to publish stories and blog posts. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Rifka Kats
The proof is in the pudding for Sagimet Biosciences (USA Stocks: SGMT), a clinical-stage biopharmaceutical company that has been making waves in the healthcare sector. With its innovative approach to treating diseases resulting from dysfunctional lipid metabolism pathways, Sagimet Biosciences is poised for a potential upside by December 2023. The company's lead drug candidate, Denifanstat, is a fatty acid synthase inhibitor that is currently being developed for the treatment of nonalcoholic steatohepatitis and acne.
| over a week ago at Macroaxis By Gabriel Shpitalnik |  |
As we approach the end of 2023, Ryvyl Inc. (USA Stocks: RVYL), a prominent player in the Software - Infrastructure industry, presents an intriguing investment opportunity. Despite a challenging year with an estimated loss of $10.36 per share, the company's stock has shown resilience with a day typical price of $3.78, significantly above the Wall Street target price of $2.5. With a 52-week high of $17.5, the potential for substantial growth is evident.
| over a week ago at Macroaxis By Ellen Johnson |  |
As we approach the end of the year, investors are keenly watching GreenTree Hospitality Group, a leading player in the Consumer Cyclical sector, specifically in the Hotels, Resorts & Cruise Lines concentration. The company, listed on the NYSE, has had a volatile year, with its stock price oscillating between a 52-week low of $2.54 and a high of $6.78. However, with a recent uptick in its 50-day moving average to $4.382, slightly above its valuation market value of $4.39, there are signs that a reversal may be on the horizon.
| over a week ago at Macroaxis By Raphi Shpitalnik |  |
Four Seasons Education (FEDU), a prominent player in the Education Services sector, has been under the financial microscope since its IPO on the 8th of November 2017. Despite a Wall Street target price of $4.37, the company's current valuation market value stands at $9.4, suggesting a potential undervaluation. As of the 19th of November 2023, the naive expected forecast value for FEDU is $10.52, indicating a promising upside.
| over two weeks ago at Macroaxis By Vlad Skutelnik |  |
Every cloud has a silver lining, and the current situation with Catalent Inc. (NYSE: CTLT) seems to be no exception. Despite the unfavorable news, there appears to be potential investment opportunities. The pharmaceutical company's typical day price stands at $38.72, a considerable drop from its 52-week high of $74.49.
| over two weeks ago at Macroaxis By Aina Ster |  |
Local Bounti Corp's stock has been on an impressive rally, with a price percent change of 22.14% and a potential upside of 11.49%. Despite the company's negative income, with an EPS estimate for the current year reported as a loss of 10.17, the stock's 200-day moving average stands at 5.4006, indicating a positive long-term trend. However, investors should consider the total risk alpha of 0.3606 and the maximum drawdown of 27.03, which suggest a higher level of risk.
| over three weeks ago at Macroaxis By Vlad Skutelnik | |
Aura Biosciences, Inc. (NASDAQ: AURA), a biotechnology company specializing in the development of therapies for treating cancer, presents a promising investment opportunity. With a strong focus on tumors of high unmet need in ocular and urologic oncology, Aura Biosciences is currently developing AU-011, a virus-like drug conjugates (VDC) candidate for the treatment of primary choroidal melanoma, which is in phase III clinical trial. The company's shares have seen a 52-week high of $14.38, with a current valuation market value of $11.98.
| over three weeks ago at Macroaxis By Ellen Johnson | |
The healthcare sector is often a hotbed of investment activity, and Alpine Immune Sciences (NASDAQ: ALPN) is no exception. With a market valuation of $16.07 billion, this biotechnology firm has been on the radar of many investors. Despite an estimated loss of $1.5 per share expected next year, insiders seem bullish about the company's future growth.
| over a month ago at Macroaxis By Raphi Shpitalnik | |
Wrap Technologies has a beta of 2.1785. This suggests that the company is likely to outperform the market when it is on an upward trend. Conversely, if the market experiences negative returns, Wrap Technologies is expected to underperform.
| over a month ago at Macroaxis By Vlad Skutelnik | |